[Dopaminergic regulation of the hypothalamo-hypophyseal system in patients with hypophyseal adenomas]. 1989

M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov

A study was made of the state of the hypothalamohypophyseal system in patients with different types of chromophobe adenoma. Altogether 62 patients were examined using metoclopramide and Parlodel tests (38 patients were with somatotropinoma, 13--with prolactinoma, 11--with somatotropinoma with hyperprolactinemia). The time course of STH, PRL and TSH secretion in the blood was investigated. Dopaminergic blockade in the Metoclopramide test was shown to cause no change in the time course of PRL secretion in patients with prolactinomas, and a PRL reaction in patients with somatotropinomas and adenomas with PRL and STH hypersecretion was sharply decreased. A paradoxical STH reaction (a decrease) in somatotropinomas and considerable disorders in the type of PRL and TSH secretion in all forms of adenomas was defined in the Parlodel test (a dopaminergic agonist). The results obtained suggest considerable disorders in the dopaminergic regulation of the hypothalamohypophyseal system of patients with chromophobe adenomas and the efficacy of the metoclopramide and Parlodel tests in the differential diagnosis of these conditions.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D008297 Male Males
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010911 Pituitary Neoplasms Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA. Pituitary Cancer,Cancer of Pituitary,Cancer of the Pituitary,Pituitary Adenoma,Pituitary Carcinoma,Pituitary Tumors,Adenoma, Pituitary,Adenomas, Pituitary,Cancer, Pituitary,Cancers, Pituitary,Carcinoma, Pituitary,Carcinomas, Pituitary,Neoplasm, Pituitary,Neoplasms, Pituitary,Pituitary Adenomas,Pituitary Cancers,Pituitary Carcinomas,Pituitary Neoplasm,Pituitary Tumor,Tumor, Pituitary,Tumors, Pituitary
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis

Related Publications

M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1986, Ceskoslovenska fysiologie,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
March 1973, Ceskoslovenska fysiologie,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1994, Problemy endokrinologii,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1974, Ceskoslovenska fysiologie,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1976, Ceskoslovenska fysiologie,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
July 1951, El Dia medico,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
March 1986, Nihon rinsho. Japanese journal of clinical medicine,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1956, Revue medicale de la Suisse romande,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
September 1984, Fiziologicheskii zhurnal SSSR imeni I. M. Sechenova,
M I Balabolkin, and G A Gerasimov, and R Ia Snigireva, and I V Pisarskaia, and A V Liubimov
January 1977, Ceskoslovenska fysiologie,
Copied contents to your clipboard!